What is PMOS?

What is PMOS?

Despite what the name suggests, Polyendocrine Metabolic Ovarian Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PMOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.

At its core, PMOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PMOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PMOS so challenging—and why understanding your unique experience matters.

So, how can the PMOS Association help?

We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PMOS—and make progress.

Here’s what you’ll find at PMOSA:

  • Reliable, science-backed information about what PMOS is (and isn’t)

  • 💬 Supportive communities of people who understand exactly what you’re going through

  • 🧬 Resources for navigating fertility, metabolic health, nutrition, and more

  • 🧠 Education for providers who want to better support their PMOS patients

  • 🙋‍♀️ Advocacy to make sure PMOS is recognized, researched, and respected

No fluff. No fad cures. Just real support, grounded in evidence and compassion.

At PMOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.

pcos

pcos: Latest results from PubMed

Research progress on traditional Chinese medicine in prevention and treatment of metabolic diseases via SIRT1/AMPK signaling pathway

Metabolic diseases, characterized by systemic dysregulation of glucose, lipid, protein, and energy homeostasis, encompass a cluster of multisystem disorders and have emerged as a critical global public health challenge. The silent information regulator 1(SIRT1)/adenosine monophosphate-activated protein kinase(AMPK) signaling pathway serves as a central hub for cellular energy sensing and stress response. By synergistically promoting downstream effectors such as peroxisome proliferator-activated...

Published on: Thu, 03 Sep 2026 06:00:00 -0400

Authors: Jin-Peng Hu, Sai Zhang, Li-Jun Yan, Qi-Yuan Yao, Hong Gao,

Methyl indole-3-acetate mediates myricetin-induced brown adipose tissue activation and reproductive-metabolic improvement in PCOS mice

Polycystic ovary syndrome (PCOS) is frequently associated with alterations in gut microbiota composition, although the specific microbial metabolites that influence ovarian function remain incompletely understood. Myricetin has been reported to improve reproductive and metabolic features in experimental PCOS models and to activate brown adipose tissue (BAT); however, whether these effects are mediated by the gut microbiota has not been clarified. In dehydroepiandrosterone (DHEA)-induced PCOS...

Published on: Thu, 03 Sep 2026 06:00:00 -0400

Authors: Mingming Wang, Chaolong Wang, Yiqiu Li, Haiying Fu, Wenjie Lu, Yi Zhao, Jing Liu, Tao Hu,

The role of metabolic variables of serum uric acid beyond polycystic ovary syndrome (PCOS) phenotypes

No abstract

Published on: Thu, 03 Sep 2026 06:00:00 -0400

Authors: Megha Haresh Raheja,

Inflammation Targeting Lymphocyte Apoptotic Body Hybrid Nanovesicles Alleviate Ovarian Inflammation in Polycystic Ovary Syndrome

Sustained inflammation localized in the ovarian microenvironment has been implicated as a key pathophysiological driver of polycystic ovary syndrome (PCOS), primarily disrupting normal folliculogenesis and arresting ovulation. Current therapies generally fail to address this underlying pathology due to their limitation in precisely targeting or modulating the ovarian immune microenvironment. Consequently, inflammation-induced tissue damage remains largely unresolved. To overcome this limitation,...

Published on: Thu, 03 Sep 2026 06:00:00 -0400

Authors: Xuezhi Shen, Qifan Yu, Yanhong Shen, Bufan Zhang, Xiaohang Ye, Yuewen Ying, Yiqing Wu, Xiao Sun, Dan Zhang, Yifeng Liu,

The impact of gut microbiota on insulin resistance in polycystic ovary syndrome: mechanisms and therapeutic prospects

Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder, with insulin resistance (IR) serving as its core pathophysiological feature and a key driver of long-term metabolic complications. Recent studies have revealed that the gut microbiota, as a critical environmental factor, plays a significant role in the pathogenesis of PCOS. The gut microbiota profoundly engages in the pathophysiology of PCOS-IR through multiple pathways and networked interactions. This review...

Published on: Thu, 03 Sep 2026 06:00:00 -0400

Authors: Yifan Gao, Ciyan Liu, Xiaoxia He,

Androgen-Driven Dysregulation of Lipolysis in Cumulus Cells: Molecular Evidence and Metabolic Implications in Polycystic Ovary Syndrome

CONCLUSION: PCOS-associated hyperandrogenism appears to impair lipolysis in CCs, representing a potential mechanistic contributor to attendant compromised oocyte competence.

Published on: Wed, 02 Sep 2026 06:00:00 -0400

Authors: Reza Zarezadeh, Amir Fattahi, Kobra Hamdi, Saba Nikanfar, Mohammad Nouri, Masoud Darabi,

Association between dietary inflammatory index and polycystic ovary syndrome: a meta-analysis of case-control studies

CONCLUSION: Pro-inflammatory dietary patterns are modestly associated with PCOS. Although causality inference is impossible due to the design of included studies, existing evidence supports DII as a potential tool for estimating PCOS status associated with diet. The small effect size observed in this study indicates a significant association between DII and PCOS. However, statistical association does not necessarily imply practical clinical relevance, and further studies are warranted to...

Published on: Wed, 02 Sep 2026 06:00:00 -0400

Authors: Junmei Huang, Chunyan Dong, Danyi Qiu, Xiaoye Li,

From Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome: A Systematic Search and Historical Account of the Renaming of PCOS

Polyendocrine metabolic ovarian syndrome (PMOS) is one of the most common endocrine conditions affecting hundreds of millions of women globally. The former name polycystic ovary syndrome (PCOS) was inaccurate, underpinning the robust nomenclature change process. This review historically traces renaming efforts up to, including and beyond the PMOS global renaming process. A systematic search of Medline and Embase screened according to PRISMA 2020 methodology, identified 30 eligible papers...

Published on: Tue, 01 Sep 2026 06:00:00 -0400

Authors: Helena J Teede, Saeede Saadati, Rachel Morman, Mahnaz Bahri Khomami, Melanie G Cree, Robert J Norman, Terhi Piltonen,

The Effect of Exercise on Reproductive and Metabolic Outcomes in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

CONCLUSIONS: Exercise intervention alone significantly ameliorates body composition, hyperandrogenism, and certain glucose and lipid metabolic disturbances in individuals with PCOS. The benefits are modulated by exercise parameters (intensity, weekly duration) and baseline patient characteristics (geographical distribution, obesity status), highlighting the importance of individualized interventions in clinical practice.

Published on: Tue, 01 Sep 2026 06:00:00 -0400

Authors: Kangxi Zou, Yunlu Ping, Qiuyang Wei, Xiaoxuan Zhao, Ying Wang, Di Wu, Lu Chen, Shimeng Wang, Xiaoling Feng,

Integrated multi-omics analyses identify an RAS-SLC11A2-associated molecular framework linking iron metabolism with PCOS-related cardiometabolic risk

CONCLUSION: This study defines an RAS-SLC11A2 molecular framework linking iron metabolism dysregulation to PCOS-related cardiometabolic risk, elucidating the mechanisms connecting ovarian dysfunction, inflammation, oxidative stress and hypertension, and supports gentiopicroside as a promising therapeutic candidate.

Published on: Tue, 01 Sep 2026 06:00:00 -0400

Authors: Sihan Zhang, Yu Xu, Tingting Cao, Kun Wang, Lina Jia, Jianning Li,

Leptin, adiponectin levels and their ratios in women with polyendocrine metabolic ovarian syndrome: a systematic review and meta-analysis

CONCLUSION: Women with PMOS aged 18-49 exhibit higher leptin levels, lower adiponectin levels and a lower A/L ratio. Further well-designed adequately powered prospective studies are needed to clarify the association between these markers and PMOS, including assessments of their sensitivity, specificity, and optimal cutoff values for predicting PMOS risk.

Published on: Tue, 01 Sep 2026 06:00:00 -0400

Authors: Xiaomeng Shi, Wenting Zhang,

From polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: rationale, evidence, and implications of a global name change

No abstract

Published on: Tue, 01 Sep 2026 06:00:00 -0400

Authors: Abdinasir Adam Shidane, Zakariye Isak Mohamed, Muhammad Umair Manzoor, Muhammad Owais, Sakina Ali,

Effects of ketone supplementation on metabolic and hormonal profiles in polycystic ovary syndrome: A systematic review and meta-analysis

CONCLUSION: Ketone supplementation appears to confer significant metabolic and endocrine benefits in women with PCOS, including reductions in BMI, glucose, insulin, LH, and androgens, along with increases in FSH and estrogen.

Published on: Tue, 01 Sep 2026 06:00:00 -0400

Authors: Sajjad Ahmed Khan, Sabah Kulsum, Anuj Subedi, Anurag Marasini, Alisha Shrestha, Tarun Pradhan, Jiba Nath Dhamala, Benju Pandit, Sadab Khan, Huma Kausar,

Comment on "Effect of Semaglutide with Metformin for Weight Loss and Fertility in Polycystic Ovary Syndrome (PCOS) Patients with Obesity: A Pilot Prospective Study"

No abstract

Published on: Mon, 31 Aug 2026 06:00:00 -0400

Authors: Sridhar Siddiraju, Neelimarani Tumma, Surendra Singh,

Reply - Letter to the editor: Comment on "effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study

No abstract

Published on: Mon, 31 Aug 2026 06:00:00 -0400

Authors: Tomáš Bolek, Martin Jozef Péč, Ivana Ságová, Jakub Jurica, Matej Samoš, Petra Turňová,